Arca
Skip to content
Tools
Tools

Visibly Digital Acuity Product

Digital Visual Acuity Test. 510(k) K220090, from Visibly, Inc. (Chicago, IL). Product code QTO, class 1.

As of Nov 19, 2026, K220090 is an FDA 510(k) held by Visibly, Inc., substantially equivalent on Aug 12, 2022 after 213 days, with no recalls tied to it in FDA's recall database.

  • Review time: 213 days
  • Recalls: 0

Indications for use

As the 510(k) summary states them, read from FDA's summary PDF

The Visibly Digital Acuity Product (VDAP) is a web-based, self-guided software application intended for use by adults, ages 22 to 40, who have the capability to perform a self-test at home, to aid in the evaluation of visual acuity with or without correction.

Predicate devices

The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF

Record

Type
Traditional
Received
Jan 11, 2022
Review panel
Ophthalmic
Regulation
21 CFR 886.1150

One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.